Vivimed Labs Gets Zero US FDA Observations, Stock Surges By 6.5%


Vivimed Labs on Tuesday informed the BSE that its API manufacturing facility in Sant Celoni, Spain was recently inspected by the US FDA. It has been granted zero 483 observations by the regulator.

The company has delivered over 35% returns in a year’s time. It has outperformed the BSE Healthcare and underperformed and BSE small-cap over the same period.

Meanwhile, Vivimed Labs was up by 6.5% at Rs 111.90 per share at 10:09 hours IST on BSE. It hit a high of Rs 113.90 and a low of Rs 109.25 during morning hours.

Vivimed Labs Limited is a pharmaceutical and chemical products company. The healthcare vertical of the company is engaged in the custom manufacturing engagements for active pharmaceutical ingredients (APIs) and formulations for generics-manufacturing companies.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: